Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenstrom's Macroglobulinemia (WM)

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenstrom's Macroglobulinemia (WM)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zanubrutinib (Primary) ; Bendamustine; Cyclophosphamide; Dexamethasone; Ibrutinib; Rituximab
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPEN
  • Sponsors BeiGene

    • Most Recent Events

    • 05 Nov 2024 According to a BeiGene media release, data from LTE study of patients with Waldenstrom macroglobulinemia (WM) from this Phase 3 ASPEN study, will be presented, at the 66th ASH Annual Meeting and Exposition in San Diego, Dec 7-10.
    • 16 Oct 2024 According to a BeiGene media release, data from an analysis of the Phase 3 ASPEN study demonstrating that peripheral neuropathy (PN) symptom resolution with BTK inhibitors correlates with depth of disease response, with faster symptom resolution with BRUKINSA than ibrutinib in patients achieving PN resolution will be presented at at the 12th International Workshop on Waldenstrom Macroglobulinemia (IWWM) Oct. 17-19 in Prague, Czech Republic.
    • 12 Jul 2023 Results of final analysis reporting long-term follow-up outcomes published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top